HF Post Myocardial Infarction (MI)

BGM Galectin-3™ Post MI

Based on the biology of adverse remodeling in post myocardial, or heart muscle, injury and consistent with our own observations in heart failure, we predict that elevated levels of galectin-3 will occur in a segment of patients who have suffered a myocardial injury, such as during a heart attack. We expect that elevated levels of galectin-3 in these patients are associated with an elevated risk of heart failure development. Patients surviving a heart attack remain at high risk of death from adverse remodeling. According to the American Heart Association, an estimated 8.5 million Americans alive today have suffered a heart attack, with an approximate 935,000 new or recurring heart attacks occurring each year in the United States and, we believe the prevalence and incidence of heart failure are similar in Europe.

We are currently conducting a case control study to investigate the performance of galectin-3 measurement as a predictor of future heart failure development in patients following acute coronary syndrome before the onset of signs and symptoms.

* The BGM Galectin-3 Test (pending 510(k)) is not available for sale within the United States and is not authorized for sale in Canada.